528205

PAI-1

Human, recombinanat, ≥98% (SDS-PAGE), Tissue plasminogen activator (tPA) inhibitor, liquid

• Synonym(e): PAI-1
• UNSPSC Code: 12352200
• NACRES: NA.77
• Assay: ≥98% (SDS-PAGE)
• Form: liquid
• Storage condition: OK to freeze, avoid repeated freeze/thaw cycles

Eigenschaften

• Produktname: Plasminogen Activator Inhibitor-1, Human, Recombinant, The Plasminogen Activator Inhibitor-1, Human, Recombinant controls the biological activity of Plasminogen Activator. This small molecule/inhibitor is primarily used for Protease Inhibitors applications.
• Quality Segment: 100
• assay: ≥98% (SDS-PAGE)
• form: liquid
• manufacturer/tradename: Calbiochem^®
• storage condition: OK to freeze, avoid repeated freeze/thaw cycles
• shipped in: wet ice
• storage temp.: −70°C

Beschreibung

General description

PAI-1 is the primary inhibitor of both tissue plasminogen activator (tPA) and urokinase (uPA). PAI-1 can exist either in an active inhibitory conformation or in an inactive or latent conformation. This highly purified preparation has not been exposed to denaturing conditions and has been chromatographically purified of latent material. PAI-1 is a marker for acute myocardial infarction and several thrombolytic disorders. Protects platelets against the inhibitory effects of plasma. Reported to be an important prognostic factor in breast cancer patients. PAI-1 is highly stable when stored at or below pH 6.6.

Primary inhibitor of both tissue plasminogen activator (tPA) and urokinase (uPA). PAI-1 is synthesized by vascular epithelium and hepatocytes. Used as a marker for acute myocardial infarction and in the diagnosis of several thrombolytic disorders. Protects platelets against the inhibitory effects of plasma. Shown to have a role complimentary to that of α₂-anti-plasmin. Elevated levels are found in subjects with accelerated coronary artery disease. PP1 activity may limit the extent of metastasis, since uPA activity is a major contributory factor promoting dissolution of tumor matrix and basement membrane. May serve as an independent and strong prognosticator in breast cancer patients. Patients having elevated levels of PAI-1 in their primary tumors are more prone to relapse. Can exist either in an active inhibitory conformation or in an inactive or latent conformation. This highly purified preparation has not been exposed to denaturing conditions and has been chromatographically purified free of the inactive material.

Biochem/physiol Actions

Cell permeable: no

Primary Target
Tissue plasminogen activator (tPA) and urokinase (uPA)

Product does not compete with ATP.

Reversible: no

Physical form

In 150 mM NaCl, 50 mM sodium phosphate buffer, 1 mM EDTA, pH 6.6.

Preparation Note

Following initial thaw, aliquot and freeze (-70°C).

Other Notes

Vaughan, D.E., et al. 1995. J. Clin. Invest. 95, 995.
Dimitri, G., et al. 1993. Boll. Chim. Farmaceutico 132, 272.
Janicke, F., et al. 1993. Breast Cancer Res. Treatment 24, 195.
Klasser, K.J., et al. 1993. Coron. Artery Dis. 4, 713.
Robbie, L.A., et al. 1993. Thromb. Hemost.70, 307.
Lawrence, D., et al. 1989. Eur. J. Biochem.186, 523.
Collen, D. and Lijnen, H.R. 1987. In The Molecular Basis of Blood Diseases (Stamatoyannopoulus, G., et al. Eds.) W.B. Saunders
Ginsberg, D., et al. 1986. J. Clin. Invest.78, 1673.
Vassalli, J.D., et al. 1985. J. Cell Biol.100, 86.

Legal Information

CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany

Disclaimer

Toxicity: Standard Handling (A)

Sicherheitshinweise

• Lagerklasse: 10 - Combustible liquids
• Was ist los?: WGK 1
• Flammpunkt (°F): Not applicable
• Flammpunkt (°C): Not applicable